Skip to main content
Erschienen in: Osteoporosis International 5/2014

01.05.2014 | Original Article

Comparison of two commercially available ELISAs for circulating sclerostin

verfasst von: A. G. Costa, S. Cremers, E. Dworakowski, M. Lazaretti-Castro, J. P. Bilezikian

Erschienen in: Osteoporosis International | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Summary

This study investigates the performance and correlation of sclerostin measurements by two commercially available sclerostin ELISAs from TECOmedical and Biomedica. We found that the correlation between the results of two sclerostin assays is strong.

Introduction

Circulating sclerostin levels may provide insight into the pathophysiology of metabolic bone diseases such as osteoporosis. However, recent studies suggest that commercially available assays give different results. We compare the analytical performance of the two most used commercially available sclerostin ELISAs from TECOmedical and Biomedica.

Methods

Sclerostin levels were assessed in 20 paired serum, EDTA, and heparin plasma convenience samples from hospitalized patients. In addition, sclerostin was measured in serum samples from 34 patients with metabolic bone diseases and from 10 patients with chronic kidney disease (CKD). Samples from three healthy donors were used to determine stability and intra- and inter- assay precision.

Results

The average serum sclerostin concentration of all patients (n = 64) was 0.713 ± 0.58 ng/mL with the Biomedica assay and 0.734 ± 0.43 ng/mL with the TECO assay (p < 0.05). The results correlated strongly (r = 0.9; p < 0.0001), with Passing-Bablok regression showing a linear relationship but with a slight systematic and proportional difference between both assays. Sclerostin levels were about 30 % higher in plasma than in serum for both assays, while no significant difference was seen between EDTA and heparin plasma. Intra- and inter- precision were <10 % for TECO and <20 % for Biomedica. Samples were stable for up to three freeze-thaw cycles with both assays.

Conclusions

The two commercially available ELISAs for measuring circulating levels of sclerostin are comparable. However, given the small but statistically significant systematic and proportional differences between both assays, results and reference ranges will be assay-specific. Results will also be specific to serum or plasma.
Literatur
1.
Zurück zum Zitat van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199(6):805–814. doi:10.1084/jem.20031454 PubMedCentralPubMedCrossRef van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199(6):805–814. doi:10.​1084/​jem.​20031454 PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95(11):5056–5062. doi:10.1210/jc.2010-0720 PubMedCentralPubMedCrossRef Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95(11):5056–5062. doi:10.​1210/​jc.​2010-0720 PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Kaji H, Imanishi Y, Sugimoto T, Seino S (2011) Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes 119(7):440–444. doi:10.1055/s-0031-1275661 PubMedCrossRef Kaji H, Imanishi Y, Sugimoto T, Seino S (2011) Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes 119(7):440–444. doi:10.​1055/​s-0031-1275661 PubMedCrossRef
5.
Zurück zum Zitat Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabro A, Cataldo D, Stolakis K, Dotta F, Nuti R (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97(5):1737–1744. doi:10.1210/jc.2011-2958 PubMedCrossRef Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabro A, Cataldo D, Stolakis K, Dotta F, Nuti R (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97(5):1737–1744. doi:10.​1210/​jc.​2011-2958 PubMedCrossRef
6.
Zurück zum Zitat Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G (2012) Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 90(6):473–480. doi:10.1007/s00223-012-9595-4 PubMedCrossRef Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G (2012) Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 90(6):473–480. doi:10.​1007/​s00223-012-9595-4 PubMedCrossRef
7.
Zurück zum Zitat Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 44(12):909–913. doi:10.1055/s-0032-1312618 PubMedCrossRef Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 44(12):909–913. doi:10.​1055/​s-0032-1312618 PubMedCrossRef
9.
Zurück zum Zitat Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE (2012) Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 97(10):3744–3750. doi:10.1210/jc.2012-1901 PubMedCrossRef Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE (2012) Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 97(10):3744–3750. doi:10.​1210/​jc.​2012-1901 PubMedCrossRef
10.
Zurück zum Zitat Ardawi MS, Rouzi AA, Qari MH (2012) Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab 97(10):3691–3699. doi:10.1210/jc.2011-3361 PubMedCrossRef Ardawi MS, Rouzi AA, Qari MH (2012) Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab 97(10):3691–3699. doi:10.​1210/​jc.​2011-3361 PubMedCrossRef
11.
Zurück zum Zitat Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, Saeda MY (2013) Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 56(2):355–362. doi:10.1016/j.bone.2013.06.029 PubMedCrossRef Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, Saeda MY (2013) Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 56(2):355–362. doi:10.​1016/​j.​bone.​2013.​06.​029 PubMedCrossRef
13.
Zurück zum Zitat Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD (2013) Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 24(2):489–494. doi:10.1007/s00198-012-1978-x PubMedCrossRef Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD (2013) Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 24(2):489–494. doi:10.​1007/​s00198-012-1978-x PubMedCrossRef
14.
Zurück zum Zitat van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE (2012) Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab 97(10):E1953–E1957. doi:10.1210/jc.2012-2218 PubMedCentralPubMedCrossRef van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE (2012) Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab 97(10):E1953–E1957. doi:10.​1210/​jc.​2012-2218 PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R (2013) Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 98(9):3873–3883. doi:10.1210/jc.2013-2113 PubMedCrossRef Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R (2013) Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 98(9):3873–3883. doi:10.​1210/​jc.​2013-2113 PubMedCrossRef
17.
Zurück zum Zitat Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284(16):10890–10900. doi:10.1074/jbc.M807994200 PubMedCentralPubMedCrossRef Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284(16):10890–10900. doi:10.​1074/​jbc.​M807994200 PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Lierop AH, Hamdy NAT, Bezooijen RL, Löwik CW, Papapoulos SE (2011) The role of sclerostin in the pathophysiology of sclerosing bone dysplasias. Clin Rev Bone Miner Metab 10(2):108–116. doi:10.1007/s12018-011-9123-5 CrossRef Lierop AH, Hamdy NAT, Bezooijen RL, Löwik CW, Papapoulos SE (2011) The role of sclerostin in the pathophysiology of sclerosing bone dysplasias. Clin Rev Bone Miner Metab 10(2):108–116. doi:10.​1007/​s12018-011-9123-5 CrossRef
Metadaten
Titel
Comparison of two commercially available ELISAs for circulating sclerostin
verfasst von
A. G. Costa
S. Cremers
E. Dworakowski
M. Lazaretti-Castro
J. P. Bilezikian
Publikationsdatum
01.05.2014
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 5/2014
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2635-3

Weitere Artikel der Ausgabe 5/2014

Osteoporosis International 5/2014 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.